AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial

Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).

Zhitong FinanceDec 12 07:56

Tracer Biotechnologies Announces Multi-Year Project With AstraZeneca

Benzinga03:02

Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

Businesswire03:00

Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study

Zacks Dec 12 21:00

TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95

Futu NewsDec 12 13:33 · Ratings

TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)

TipRanksDec 12 13:15 · Ratings